AACR 2026 | Transcenta Holding to Present Latest Preclinical Progress on Osemitamab (TST001) and TST013

Princeton, New Jersey, USA, and Suzhou, China, March 23, 2026 — Transcenta Holding (06628.HK), an international clinical-stage biopharmaceutical company with fully integrated capabilities in biologics discovery, research and development, process development, and manufacturing, today announced that preclinical research findings for two of the company's self-developed pipelines have been successfully selected for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. This year’s conference will take place in San Diego, USA, from April 17 to 22, 2026, local time.

The AACR Annual Meeting is a vital platform for advancing the field of oncology, bringing together scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates each year to share and discuss the latest breakthroughs in cancer treatment. Covering areas from population science and prevention to cancer biology, translational medicine, clinical research, as well as survivorship care and advocacy, the AACR conference showcases cutting-edge advancements in cancer science and medicine.

The abstract information is disclosed as follows:

Osemitamab (TST001)

Abstract Title:

Characterization of osemitamab in pancreatic cancer models and patients

Characterization study of osemitamab in pancreatic cancer models and patients

Abstract Number:2645

Report Type:Poster

Session Category:clinical research

Session Title:Redefining Targeted Therapy: Bispecific T-cell Engagers and Antibody-Drug Conjugates

Presentation Time:

April 20, 9:00 AM to 12:00 PM (US local time)

April 21, midnight 0:00-3:00 (Beijing Time)

TST013

Abstract Title:

Preclinical characterization of novel LIV1 antibody drug conjugates

Preclinical characterization of novel LIV1 antibody-drug conjugates

Abstract Number:4441

Report Type:Poster

Sub-session Category:Experimental and Molecular Therapies

Sub-session Title:Antibody-drug Conjugates and Linker Design

Presentation Time:

April 21, 9:00 AM - 12:00 PM (US local time)

April 22, midnight 0:00-3:00 (Beijing Time)

About Transcenta Group

Transcenta Group is a clinical-stage biopharmaceutical company with comprehensive capabilities in biologic drug discovery, research and development, process development, and manufacturing.

Transcent Group is headquartered in Suzhou and has successfully established a global business presence: it operates drug discovery, clinical, and translational research centers in Suzhou, a process and product development center as well as a drug manufacturing base in Hangzhou, and clinical development centers in China, the United States, and Europe. Transcent Group is developing a diversified pipeline that includes dozens of novel biologics covering oncology and non-oncology indications, including orthopedics, autoimmune diseases, and kidney disorders.

For more information about Transcenta, please visit the company website: www.transcenta.com or LinkedIn profile: Transcenta. If you are interested in exploring capital partnership opportunities, please contact us via ir@transcenta.com to discuss potential collaborations.

28K Views